iRadimed (NASDAQ:IRMD – Get Free Report) and Solana (NASDAQ:HSDT – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.
Profitability
This table compares iRadimed and Solana’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| iRadimed | 26.82% | 23.83% | 20.83% |
| Solana | -39,358.88% | -699.93% | -301.82% |
Valuation & Earnings
This table compares iRadimed and Solana”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| iRadimed | $83.81 million | 14.85 | $22.48 million | $1.75 | 55.63 |
| Solana | $520,000.00 | 152.49 | -$11.74 million | ($1,267.04) | 0.00 |
iRadimed has higher revenue and earnings than Solana. Solana is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
iRadimed has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, Solana has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings for iRadimed and Solana, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| iRadimed | 0 | 1 | 3 | 0 | 2.75 |
| Solana | 1 | 0 | 0 | 0 | 1.00 |
iRadimed presently has a consensus target price of $120.00, indicating a potential upside of 23.25%. Given iRadimed’s stronger consensus rating and higher probable upside, research analysts clearly believe iRadimed is more favorable than Solana.
Institutional & Insider Ownership
92.3% of iRadimed shares are held by institutional investors. Comparatively, 18.6% of Solana shares are held by institutional investors. 36.8% of iRadimed shares are held by insiders. Comparatively, 17.2% of Solana shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
iRadimed beats Solana on 13 of the 14 factors compared between the two stocks.
About iRadimed
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
About Solana
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.
Receive News & Ratings for iRadimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed and related companies with MarketBeat.com's FREE daily email newsletter.
